GeM Publications
Miller, D.T.; Cortés-Ciriano, I.; Pillay, N.; Hirbe, A.C.; Snuderl, M.; Bui, M.M.; Piculell, K.; Al-Ibraheemi, A.; Dickson, B.C.; Hart, J.; Jones, K.; Jordan, J.T.; Kim, R.H.; Lindsay, D.; Nishida, Y.; Ullrich, N.J.; Wang, X.; Park, P.J.; Flanagan, A.M., on behalf of the Genomics of MPNST (GeM) Consortium; Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes 2020, 11, 387.
[Link] GeM Poster: June 13, 2019 - Cancer Genetics Retreat hosted by Dana-Farber/Harvard Cancer Center
Upcoming:
[Link] Abstract submission: 2019 Annual NF Conference hosted by the Children’s Tumor Foundation in San Francisco, California
[Link] Abstract submission: 2019 Annual Connective Tissue Oncology Society (CTOS) Meeting in Tokyo, Japan
Publications by NFRI-funded researchers
The NF Research Initiative’s 2017 MPNST Pre-Clinical Research Grant Program
Karen Cichowski, PhD - Brigham and Women’s Hospital
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas” [Link] in the journal Cancer Discovery.
Conxi Lazaro, PhD - L’Hospitalet de Liobregat
Fernández-Rodríguez J, Morales La Madrid A, Gel B, Castañeda Heredia A, Salvador H, Martínez-Iniesta M, Moutinho C, Morata J, Heyn H, Blanco I, Creus-Bachiller E, Capella G, Farré L, Vidal A, Soldado F, Krauel L, Suñol M, Serra E, Villanueva A, Lázaro C. Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor. Ther Adv Med Oncol. 2020 Jul 3; 12:1758835920929579. doi: 10.1177/1758835920929579. PMID: 32670419; PMCID: PMC7339074.
The NF Research Initiative is a proud sponsor of the Children’s Tumor Foundation’s Young Investigator Awards (YIAs).
2017 YIA Recipients:
Lai Man Natalie Wu, PhD - Children’s National Medical Center
Article titled “Therapeutic targets for malignant peripheral nerve sheath tumors” [Link] in the journal Future Neurology.
Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis, Cancer Cell. 2018 Feb 12; 33(2): 292–308.e7.
Kyle Williams, PhD - University of Minnesota
Ramkissoon A, Chaney KE, Milewski D, Williams KB, Williams RL, Choi K, Miller A, Kalin TV, Pressey JG, Szabo S, Azam M, Largaespada DA, Ratner N. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clin Cancer Res. 2019 Jul 1;25(13):4117-4127. doi: 10.1158/1078-0432.CCR-18-3224. Epub 2019 Apr 1. PMID: 30936125; PMCID: PMC6606396.
Williams KB, Largaespada DA. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Genes (Basel). 2020 Apr 28;11(5):477. doi: 10.3390/genes11050477. PMID: 32353955; PMCID: PMC7290716.
2018 YIA Recipients:
Jamie Grit, PhD - Van Andel Research Institute
Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities, Genes (Basel), 2020 Mar 20;11(3):331
Dong Hyuk Ki, PhD - Dana Farber Cancer Institute
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene
2019 Sep;38(39):6585-6598.suz12 inactivation in p53- and nf1-deficient zebrafish accelerates the onset of malignant peripheral nerve sheath tumors and expands the spectrum of tumor types. Dis Model Mech,. 2020 Aug 27;13(8)
Harish Vasudevan, PhD - University of California San Francisco
Genetic Events and Signaling Mechanisms Underlying Schwann Cell Fate in Development and Cancer. Neurosurgery 2021 Jan 13;88(2):234-245
Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival. Neuro-Oncology Advances, Volume 2, Issue 1, January-December 2020
2019 YIA Recipients:
Jordan Kohlmeyer, PhD - University of Iowa
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. Int J Mol Sci 2020 Apr 24;21(8):3018.
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors. Clin Cancer Res 2020 Jun 15;26(12):2997-3011.
Related Publications Authored by GeM Collaborators
[Link] “Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways” (Cancer Cell, 2019) by Christopher D. Steele, Maxime Tarabichi,Dahmane Oukrif,Amy P. Webster, Hongtao Ye, Matthew Fittall, Patrick Lombard, Inigo Martincorena, Patrick S. Tarpey, Grace Collord, Kerstin Haase, Sandra J. Strauss, Fitim Berisha, Heli Vaikkinen, Pawan Dhami, Marnix Jansen, Sam Behjati, M. Fernanda Amary, Roberto Tirabosco, Andrew Feber, Peter J. Campbell, Ludmil B. Alexandrov,Peter Van Loo, Adrienne M. Flanagan, and Nischalan Pillay
[Link] “A molecular portrait of microsatellite instability across multiple cancers” (Nature Communications, 2017) by Isidro Cortés-Ciriano, Sejoon Lee, Woong-Yang Park, Tae-Min Kim, Peter J. Park
[Link] “Linked-read analysis identifies mutations in single-cell DNA-sequencing data” (Nature Genetics, 2019) by Craig L. Bohrson, Alison R. Barton, Michael A. Lodato, Rachel E. Rodin, Lovelace J. Luquette, Vinay V. Viswanadham, Doga C. Gulhan, Isidro Cortés-Ciriano, Maxwell A. Sherman, Minseok Kwon, Michael E. Coulter, Alon Galor, Christopher A. Walsh, and Peter J. Park
[Link] “Detecting the mutational signature of homologous recombination deficiency in clinical samples” (Nature Genetics, 2019) by Doga C. Gulhan, Jake June-Koo Lee, Giorgio E. M. Melloni, Isidro Cortés-Ciriano, and Peter J. Park
[Link] “Clinical Genomic Profiling Identifies TYK2 Mutation and Overexpression in Patients With Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors” (Cancer, 2017) by Angela C. Hirbe, MD, PhD, Madhurima Kaushal, MS, Mukesh Kumar Sharma, PhD, Sonika Dahiya, MD, Melike Pekmezci, MD, Arie Perry, MD, and David H. Gutmann, MD, PhD